Recent News

• 12.04.2025 - Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
• 12.02.2025 - Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
• 11.13.2025 - Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
• 11.07.2025 - Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
• 11.05.2025 - Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
• 10.09.2025 - Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum
• 09.08.2025 - Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
• 09.02.2025 - Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
• 08.18.2025 - Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
• 07.10.2025 - Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

Recent Filings

• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - POS AM Post-Effective amendments for registration statement
• 05.01.2024 - POS AM Post-Effective amendments for registration statement
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - POS AM Post-Effective amendments for registration statement
• 05.01.2024 - POS AM Post-Effective amendments for registration statement
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness